ArticlePharmacoEconomics - open2022

Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.

Massimiliano Bonifacio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.